A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

This study is testing a new drug called AVA6000, which is designed to selectively deliver chemotherapy into cancer cells that express a specific protein called FAP, potentially reducing side effects compared to standard chemotherapy. **You may be eligible if...** - You are 18 years or older - You have a solid tumour that has been confirmed to express FAP (fibroblast activation protein) - Your cancer is locally advanced (cannot be removed by surgery) or has spread to other organs - You have one of the following cancer types: salivary gland cancer, bladder (urothelial) cancer, ovarian cancer, breast cancer, or soft-tissue sarcoma - Your cancer has progressed after standard treatments, or standard treatments are not suitable for you - For soft-tissue sarcoma: you may be eligible if you have not yet received certain chemotherapy or if your prior doxorubicin dose was below the study threshold **You may NOT be eligible if...** - Your tumour does not test positive for FAP - You have had too much prior doxorubicin chemotherapy (above the dose threshold) - You have serious organ problems or other conditions that make participation unsafe Talk to your doctor to see if this trial is right for you.